TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Livzon Pharmaceutical Group ( (HK:1513) ) just unveiled an update.
Livzon Pharmaceutical Group Inc. has announced its 2025 first extraordinary general meeting scheduled for December 10, 2025. The meeting will address several key resolutions, including the cancellation of the Supervisory Committee, amendments to the Articles of Association, and the appointment of Ms. Wang Zhiyao as an independent non-executive Director. These changes indicate a strategic shift in the company’s governance structure, potentially impacting its operational efficiency and stakeholder engagement.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the development, production, and sale of pharmaceutical products, catering to various medical needs in the market.
YTD Price Performance: 20.79%
Average Trading Volume: 1,341,695
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.3B
See more insights into 1513 stock on TipRanks’ Stock Analysis page.